The estimated Net Worth of Ellen Rosenberg is at least $8.24 Million dollars as of 6 February 2024. Ms. Rosenberg owns over 30,000 units of Amicus Therapeutics Inc stock worth over $4,477,053 and over the last 9 years she sold FOLD stock worth over $1,075,209. In addition, she makes $2,690,700 as General Counsel, Corporate Secretary und Chief Legal Officer at Amicus Therapeutics Inc.
Ellen has made over 11 trades of the Amicus Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 30,000 units of FOLD stock worth $154,800 on 6 February 2024.
The largest trade she's ever made was exercising 35,000 units of Amicus Therapeutics Inc stock on 26 December 2023 worth over $180,600. On average, Ellen trades about 6,790 units every 80 days since 2016. As of 6 February 2024 she still owns at least 397,254 units of Amicus Therapeutics Inc stock.
You can see the complete history of Ms. Rosenberg stock trades at the bottom of the page.
Ellen S. Rosenberg J.D. serves as General Counsel, Corporate Secretary, Chief Legal Officer of the Company. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance, product launches, risk management, litigation, investigations and compliance matters. Ms. Rosenberg also has significant experience building and developing legal teams and the in-house legal function. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.
As the General Counsel, Corporate Secretary und Chief Legal Officer of Amicus Therapeutics Inc, the total compensation of Ellen Rosenberg at Amicus Therapeutics Inc is $2,690,700. There are 2 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Ellen Rosenberg is 57, she's been the General Counsel, Corporate Secretary und Chief Legal Officer of Amicus Therapeutics Inc since 2018. There are 7 older and 12 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Ellen's mailing address filed with the SEC is 47 HULFISH STREET, , PRINCETON, NJ, 08542.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris und Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: